
TITLE: WNL204687 648..654
SOURCE: Cerebral atrophy in mild cognitive.pdf
AUTHOR: 

===== DOCUMENT CONTENT =====

Cerebral atrophy in mild cognitive impairment and Alzheimer disease Rates and acceleration KelvinK.Leung,PhD ABSTRACT JonathanW.Bartlett, Objective:Toquantifytheregionalandglobalcerebralatrophyratesandassessaccelerationratesin PhD healthy controls, subjects with mild cognitive impairment (MCI), and subjects with mild Alzheimer JosephineBarnes,PhD disease(AD). EmilyN.Manning,Msc Methods:Using0-,6-,12-,18-,24-,and36-monthMRIscansofcontrolsandsubjectswithMCIand SebastienOurselin,PhD AD from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database, we calculated volume NickC.Fox,MD FortheAlzheimer’s change of whole brain, hippocampus, and ventricles between all pairs of scans using the boundary shiftintegral. DiseaseNeuroimaging Initiative Results:Wefoundnoevidenceofaccelerationinwhole-brainatrophyratesinanygroup.Therewas evidencethathippocampalatrophyratesinMCIsubjectsaccelerateby0.22%/year2onaverage(p5 0.037).TherewasevidenceofaccelerationinratesofventricularenlargementinsubjectswithMCI Correspondenceto (p50.001)andAD(p,0.001),withratesestimatedtoincreaseby0.27mL/year2(95%confidence Dr.Leung: interval0.12,0.43)and0.88mL/year2(95%confidenceinterval0.47,1.29),respectively.Apost kkleung@ucl.ac.uk hocanalysissuggestedthattheaccelerationofhippocampallossinMCIsubjectswasmainlydriven bytheMCIsubjectsthatwereobservedtoprogresstoclinicalADwithin3yearsofbaseline,withthis groupshowinghippocampalatrophyrateaccelerationof0.50%/year2(p50.003). Conclusions:Thesmallaccelerationratessuggestalongperiodoftransitiontothepathologiclos- sesseeninclinicalAD.TheaccelerationinhippocampalatrophyratesinMCIsubjectsintheADNI seemstobedrivenbythoseMCIsubjectswhoconcurrentlyprogressedtoaclinicaldiagnosisof AD.Neurology(cid:1)2013;80:648-654 GLOSSARY AD5Alzheimerdisease;ADNI5Alzheimer’sDiseaseNeuroimagingInitiative;CI5confidenceinterval;MCI5mildcognitive impairment;MCI-P5mildcognitiveimpairment-progressed;MCI-S5mildcognitiveimpairment-static;MMSE5Mini-Men- talStateExamination;KN-BSI5robustboundaryshiftintegral. Alzheimerdisease(AD)isassociatedwithhigherratesofbraintissuelossthannormalaging,1withthe rateinmildcognitiveimpairment(MCI)fallingsomewhereinbetween.2Thisimpliesincreasesinthe rateoftissueloss(i.e.,acceleration)astheindividualprogressesfromnormaltoMCIandthenonto dementiaduetoAD.3,4AsigmoidalmodeloftissuelossinAD5hasbeenproposedthatsuggeststhe rate of tissue loss first accelerates, then remains constant, and finally decelerates; however, detailed dataabouthowtheratesofregionalandglobalatrophychangeovertimearelacking.Assessinghow ratesofatrophychangeinthetransitionfromnormalagingthroughearlycognitiveimpairmentand ontodementiaduetoADisimportantforunderstandingthepresymptomaticperiodofAD,which is increasingly considered as a potential therapeutic window for disease-modification trials. Anumberofstudieshaveinvestigatedaccelerationinregionalandglobalatrophyratesinnormal aging,MCI,andclinicallydiagnosedAD,withmostmodelingtissuelossasafunctionofageortime from a particular clinical stage (e.g., at the time of AD dementia diagnosis or Mini-Mental State Supplementaldataat www.neurology.org FromtheDementiaResearchCentre(K.K.L.,J.W.B.,J.B.,E.N.M.,S.O.,N.C.F.),UCLInstituteofNeurology,QueenSquare,London;Centre forMedicalImageComputing(K.K.L.,S.O.),UniversityCollegeLondon;andDepartmentofMedicalStatistics(J.W.B.),LondonSchoolof HygieneandTropicalMedicine,London,UK. DatausedinpreparationofthisarticlewereobtainedfromtheAlzheimer’sDiseaseNeuroimagingInitiative(ADNI)database(adni.loni.ucla.edu).As such,theinvestigatorswithintheADNIcontributedtothedesignandimplementationofADNIand/orprovideddatabutdidnotparticipateinanalysis orwritingofthisreport.AcompletelistingofADNIinvestigatorscanbefoundontheNeurology®Websiteatwww.neurology.org. GotoNeurology.orgforfulldisclosures.Fundinginformationanddisclosuresdeemedrelevantbytheauthors,ifany,areprovidedattheendofthearticle. 648 ©2013AmericanAcademyofNeurology (cid:170)(cid:1)(cid:19)(cid:17)(cid:18)(cid:20)(cid:1)(cid:34)(cid:78)(cid:70)(cid:83)(cid:74)(cid:68)(cid:66)(cid:79)(cid:1)(cid:34)(cid:68)(cid:66)(cid:69)(cid:70)(cid:78)(cid:90)(cid:1)(cid:80)(cid:71)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90)(cid:15)(cid:1)(cid:54)(cid:79)(cid:66)(cid:86)(cid:85)(cid:73)(cid:80)(cid:83)(cid:74)(cid:91)(cid:70)(cid:69)(cid:1)(cid:83)(cid:70)(cid:81)(cid:83)(cid:80)(cid:69)(cid:86)(cid:68)(cid:85)(cid:74)(cid:80)(cid:79)(cid:1)(cid:80)(cid:71)(cid:1)(cid:85)(cid:73)(cid:74)(cid:84)(cid:1)(cid:66)(cid:83)(cid:85)(cid:74)(cid:68)(cid:77)(cid:70)(cid:1)(cid:74)(cid:84)(cid:1)(cid:81)(cid:83)(cid:80)(cid:73)(cid:74)(cid:67)(cid:74)(cid:85)(cid:70)(cid:69)(cid:15) Examination [MMSE] score).3,4,6-8 Other stud- usingmultipleatlaspropagationandsegmentation,19,20andthelateral ieshavemodeledthetissuelossasafunctionof ventriclesweresemiautomaticallydelineatedusingtheMedicalImage time from study baseline.9-11 The Alzheimer ’ s DisplayandAnalysisSoftware.21Theimagesfromalltimepointsof eachsubjectwereaffinelyregisteredintoamiddleposition,22inorder Disease Neuroimaging Initiative (ADNI) pro- to provide consistent volume-loss estimation over multiple time vides an opportunity to investigate the time points.Symmetricdifferentialbiascorrectionwasperformedonthe transformedimages.22,23Volumelossbetweenany2imageswascal- course of atrophy because of its large size and culatedbyKN-BSI18overthewholebrain,thehippocampus,andthe consistentlongitudinalimaging.Herein,weuse lateralventricles. data from the ADNI to quantify the regional Statisticalanalysis. Baselinecharacteristicsofsubjectswithusable and global cerebral atrophy rates and accelera- scanswerecomparedwiththoseofsubjectswithoutusablescans,sep- tion in rates in healthy controls and MCI sub- aratelyineachgroup,usingttests(forage),Wilcoxonranksumtests jectswithupto3yearsoffollow-upandsubjects (forMMSE),andFisherexacttests(forgenderandAPOEe4status). Separatelyforeachgroup,annualizedatrophyrateswerecalcu- clinicallydiagnosedwithmildADwithupto2 latedfor0-12,12-24,and24-36monthsusingthecorresponding years of follow-up. scanpairs,accountingfortheintervalindaysbetweenthescans. Whole-brainandhippocampalatrophyrateswereexpressedasper- METHODS Subjects. Datausedinthepreparationofthisarti- centageofinitialvolume,whereastheventricularexpansionrate clewereobtainedfromtheADNIdatabase(adni.loni.ucla.edu)(see wasexpressedasabsolutelossinmilliliters.Weusedthesumofthe appendixe-1ontheNeurology®Websiteatwww.neurology.org). volumelossesintheleftandrighthippocampiasthetotallossinthe Forup-to-dateinformation,seewww.adni-info.org. hippocampus.Separatelyineachsubjectgroup,logisticregression Ourimagedataconsistedof0-,6-,12-,18-,24-,and36-month models were used to investigate whether atrophy during 0-12 T1-weightedmagneticresonancescansofhealthycontrols,subjects monthswaspredictiveofavailabilityofscanpairsbetween12-24 withMCI,andsubjectswithclinicallydiagnosedADdownloaded and24-36months. from the ADNI database ( over To test for and estimate acceleration in atrophy rates, linear thecourseoftheADNIstudy,withthelatestdownloadinDecember mixedmodelswerefittedseparatelyineachsubjectgrouptoallof 2011.TheindividualADNIsubjectidentifiersandtimepointsused the available direct measures of loss between scans from 2 time inthisstudycanbefoundinappendixe-2. points.24Themodelcontainedfixedeffectsoftimeandtimesquared (toallowforacceleration),andrandomsubjecteffectsoftime.The Standard protocol approvals, registrations, and patient latteraccommodatestherepeatedmeasuresfromsubjects,andallows consents. TheADNIwasapprovedbytheinstitutionalreview the(linear)atrophyratetovarybetweensubjects.Noconstantterms boardateachsiteandwascompliantwiththeHealthInsurance wereincluded,consistentwithanassumptionthatthelossbetween2 PortabilityandAccountabilityAct.Writtenconsentwasobtained scansacquiredonthesamedayshouldonaveragebezero.Wefitted fromallparticipants. modelsonthelogarithmicscaleforthewholebrainandhippocam- Image acquisition and preprocessing. Each individual was pus,wherezeroaccelerationcorrespondstoconstantpercentageatro- scannedwith a numberof sequences, but forthis study we used phyperyearandontheabsolutescalefortheventricles,wherezero theT1-weightedvolumetricscans.Representativeimagingparame- accelerationimpliesaconstantabsolutelossperyear.Modelswere terswereasfollows:repetitiontime52,300milliseconds;inversion fittedbymaximumlikelihoodusingthextmixedcommandinStata time51,000milliseconds;echotime53.5milliseconds;flipangle 12.1 (StataCorp, College Station, TX). Maximum likelihood esti- 58°;fieldofview52403240mm;and160sagittal1.2-mm- matesareconsistentprovidedthatatrophymeasuresaremissingat thickslicesanda1923192matrixyieldingavoxelresolutionof random(i.e.,theprobabilitythatameasurementismissingisinde- 1.2531.2531.2mm,or180sagittal1.2-mm-thicksliceswitha pendentofthemeasurementitself,givenobserveddata).25 2563256matrixyieldingavoxelresolutionof0.9430.943 1.2 mm. The full details of the ADNI MRI protocol have been previously described,12 and are listed on the ADNI RESULTS WedownloadedMRIscansof840subjects, Web site ( Each and excluded 74 subjects who had only baseline scans examination underwent a quality-control evaluation at the Mayo and53subjectswhofailedourinternalqualitycontrol. Clinic(Rochester,MN).Qualitycontrolincludedinspectionofeach Although there was evidence (p 5 0.047) that APOE incoming image file for protocol compliance, clinically significant e4statusoftheexcludedADsubjects(16noncarriers,18 medicalabnormalities,andimagequality.Theimagesalsounderwent heterozygotes, and 2 homozygotes) was different from internalqualitycontrolattheDementiaResearchCentre,andthose theincludedADsubjects(49noncarriers,73heterozy- withsignificantmotionartifactscausingsevereblurringatthetissue boundaries were excluded from the current study. Therefore, only gotes,and34homozygotes),therewasnoevidencethat subjectswithausablebaselinescanandatleastoneusablefollow- the 713 subjects included in this study were different upscanwereincludedinthecurrentstudy.TheT1-weightedvolu- from the 127 excluded subjects regarding age, MMSE metricscansthatpassedthequalitycontrolwereprocessedusingthe score,gender,orAPOEe4statusinothergroups(p. standardADNIimageprocessingpipeline,whichincludedthecorrec- 0.10,allothertests).Table1showsthedemographicsof tionsofgradientwarping,13B1nonuniformity,14intensitynonunifor- the713subjectsandthenumberofscanpairsavailable mity,15andscanner-driftscaling.16 (forconsecutivescans)bysubjectgroup.Asexpected,the Volume-lossmeasurement. Volumelossinthewholebrain,hip- numberofsubjectswithscansavailabledecreasedasthe pocampus,andlateralventriclesbetweeneverypairofscansforeach study progressed. Although not statistically significant, subject was measured using the robust boundary shift integral (referredtoasKN-BSI),17,18 asdescribedbelow.Thewholebrain logistic regression analyses (run separately by subject and the hippocampi in each image were automatically delineated group) suggested that those controls and AD subjects Neurology80 February12,2013 649 (cid:170)(cid:1)(cid:19)(cid:17)(cid:18)(cid:20)(cid:1)(cid:34)(cid:78)(cid:70)(cid:83)(cid:74)(cid:68)(cid:66)(cid:79)(cid:1)(cid:34)(cid:68)(cid:66)(cid:69)(cid:70)(cid:78)(cid:90)(cid:1)(cid:80)(cid:71)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90)(cid:15)(cid:1)(cid:54)(cid:79)(cid:66)(cid:86)(cid:85)(cid:73)(cid:80)(cid:83)(cid:74)(cid:91)(cid:70)(cid:69)(cid:1)(cid:83)(cid:70)(cid:81)(cid:83)(cid:80)(cid:69)(cid:86)(cid:68)(cid:85)(cid:74)(cid:80)(cid:79)(cid:1)(cid:80)(cid:71)(cid:1)(cid:85)(cid:73)(cid:74)(cid:84)(cid:1)(cid:66)(cid:83)(cid:85)(cid:74)(cid:68)(cid:77)(cid:70)(cid:1)(cid:74)(cid:84)(cid:1)(cid:81)(cid:83)(cid:80)(cid:73)(cid:74)(cid:67)(cid:74)(cid:85)(cid:70)(cid:69)(cid:15) Table1 DemographicsandMRIdataofcontrolsandsubjectswithMCIandADforthemainanalysis,andMCI-SandMCI-Psubjectsforthe posthocanalysisa Mainanalysis Posthocanalysis Control,n5205 MCI,n5352 AD,n5156 MCI-S,n5185 MCI-P,n5147 No.ofmen(%) 109(53) 225(65) 83(53) 121(65) 88(60) Age,y 76.0(5.1) 75.0(7.2) 74.9(7.7) 75.6(7.3) 74.6(6.9) MMSEscore,of30 29.1(1.0) 27.0(1.8) 23.4(1.9) 27.2(1.8) 26.7(1.7) Education,y 16.0(2.87) 15.7(2.98) 14.8(3.09) 15.7(3.15) 15.7(2.85) No.ofAPOEe4heterozygotes(%) 50(24.3) 151(42.9) 73(46.8) 70(37.8) 76(51.7) No.ofAPOEe4homozygotes(%) 5(2.4) 43(12.2) 34(21.8) 16(8.6) 26(17.7) No.ofscanpairs 0-6mo 188 315 141 162 134 6-12mo 173 272 112 131 126 12-18mo - 241 - 120 110 18-24mo - 201 - 100 90 12-24mo 142 207 80 101 96 24-36mo 108 131 - 59 64 Abbreviations:AD5Alzheimerdisease;MCI5mildcognitiveimpairment;MCI-P5MCIsubjectsobservedtoprogresstoaclinicaldiagnosisofADwithin3 years;MCI-S5MCIsubjectsobservedtoremaininMCIwithin3years;MMSE5Mini-MentalStateExamination. aDataaremean(SD)unlessstatedotherwise. withhigherwhole-brainatrophyratesbetween0and12 MCIsubjectsinbetween.Withoutconsideringstatisti- monthswerelesslikelytohavea12-to24-monthscan cal significance, the means in table 2 suggest that pair available (odds ratio for 1% increase in 0- to 12- atrophy rates (brain, hippocampal, and ventricular monthbrainatrophyincontrols0.81[95%confidence enlargement) are increasing in both the MCI and AD interval{CI}0.42,1.54],p50.52,andinADsubjects subjects over time. In controls, the only consistent 0.70[95%CI0.42,1.17],p50.18).Therewasalsothe increaseisforhippocampalrates. suggestionthatthoseMCIandADsubjectswithhigher Table 3 shows the model-estimated atrophy rates rates of brain atrophy between 0 and 12 months were and acceleration, and plots of the corresponding data lesslikelytohavea24-to36-monthscanpairavailable onanindividualbasisareincludedinthesupplemental (oddsratioincontrols0.71[95%CI0.41,1.22],p5 material(seefigurese-1ande-2).Forwhole-brainatro- 0.21, and inMCI subjects 0.83 [95%CI 0.62, 1.13], phy,therewasnoevidenceofacceleration(onaverage) p50.24).Thissuggeststhatthosesubjectswhounder- inanygroup.Furthermore,the95%CIsfortheaccel- wentscanningat24and36monthsmayhavesystem- erationarenarrowforcontrolsandMCIs,suggestingwe aticallylowerwhole-brainatrophyratesthanthosewho canbereasonablyconfidentthatifaveragewhole-brain didnot,andthatestimatesofatrophyratesinthelatter atrophy accelerationdiffers intruth fromzero inthese partofthestudybasedonthosewithscansavailableat groups, it is very close to zero. There was statistically the later time points may be biased as estimates of the significantevidenceofaccelerationforhippocampalvol- populationmeanrate. umelossinMCIsubjects(p50.037),withratesesti- In table 2, we report mean (and 95% CI) atrophy matedtoincreaseonaverage(acrosssubjects)by0.22%/ ratesusingdataonlyfromsubjectswhohadscanpairs year2(95%CI0.01,0.42).Therewasevidenceofaccel- available for all periods: 0-12, 12-24, and 24-36 erationinratesofventricularenlargementinMCI(p5 months.Althoughtheseratesmaybebiaseddownward, 0.001) and AD (p , 0.001) subjects, with rates esti- theyaremorelikelytogiveanunbiasedrepresentation mated to increase by 0.27 mL/year2 (95% CI 0.12, of how rates change over time than if rates were pre- 0.43) and 0.88 mL/year2 (95% CI 0.47, 1.29) in sentedforeachperiodbasedonscanpairsavailablefor MCIandADsubjects,respectively. thatperiod.Afurtherlimitationoftheseestimatesisthat theyarebasedonamuchsmallersubsetofsubjects,and Post hoc analysis. We hypothesized that the observed consequently they are less precise. Table 2 also shows accelerationinhippocampalratesinMCIsubjectswas linearmixedmodel-basedestimatesofatrophyratefor amanifestationofthoseMCIsubjectswhoprogressed the period, using information from all subjects. As toaclinicaldiagnosisofADduringthestudy.Wethere- expected, atrophy rates (and ventricular enlargement) fore performed a post hoc analysis in 2 subgroups of are highest in AD subjects, lowest in controls, with MCI subjects: MCI-P (MCI subjects that progressed 650 Neurology80 February12,2013 (cid:170)(cid:1)(cid:19)(cid:17)(cid:18)(cid:20)(cid:1)(cid:34)(cid:78)(cid:70)(cid:83)(cid:74)(cid:68)(cid:66)(cid:79)(cid:1)(cid:34)(cid:68)(cid:66)(cid:69)(cid:70)(cid:78)(cid:90)(cid:1)(cid:80)(cid:71)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90)(cid:15)(cid:1)(cid:54)(cid:79)(cid:66)(cid:86)(cid:85)(cid:73)(cid:80)(cid:83)(cid:74)(cid:91)(cid:70)(cid:69)(cid:1)(cid:83)(cid:70)(cid:81)(cid:83)(cid:80)(cid:69)(cid:86)(cid:68)(cid:85)(cid:74)(cid:80)(cid:79)(cid:1)(cid:80)(cid:71)(cid:1)(cid:85)(cid:73)(cid:74)(cid:84)(cid:1)(cid:66)(cid:83)(cid:85)(cid:74)(cid:68)(cid:77)(cid:70)(cid:1)(cid:74)(cid:84)(cid:1)(cid:81)(cid:83)(cid:80)(cid:73)(cid:74)(cid:67)(cid:74)(cid:85)(cid:70)(cid:69)(cid:15) Table2 Annualizedatrophyrateinwholebrain,hippocampus,andventriclesaccordingtotimeperiodrelativetobaseline,andcorresponding estimatesfromlinearmixedmodelsa Control MCI AD Modelestimate Mean(95%CI), (95%CI), Mean(95%CI), Modelestimate Mean(95%CI), Modelestimate n593 n5205 n5104 (95%CI),n5352 n572 (95%CI),n5156 Brainatrophyrate,%/y 0-12mo 0.50(0.39,0.61) 0.62(0.55,0.69) 0.89(0.75,1.02) 1.02(0.94,1.09) 1.35(1.19,1.51) 1.46(1.34,1.59) 12-24mo 0.76(0.65,0.86) 0.60(0.56,0.65) 0.99(0.83,1.14) 1.03(0.96,1.09) 1.58(1.42,1.74) 1.55(1.41,1.68) 24-36mo 0.47(0.34,0.60) 0.59(0.52,0.67) 1.07(0.90,1.24) 1.04(0.94,1.13) - - Hippocampalatrophyrate,%/y 0-12mo 1.22(0.86,1.58) 1.26(1.01,1.51) 3.54(3.00,4.08) 3.31(3.00,3.62) 5.38(4.68,6.08) 5.42(4.89,5.95) 12-24mo 1.52(1.10,1.94) 1.32(1.15,1.49) 3.59(2.92,4.26) 3.52(3.24,3.80) 5.87(5.14,6.60) 5.88(5.29,6.47) 24-36mo 1.64(1.10,2.17) 1.38(1.11,1.65) 3.78(3.22,4.35) 3.73(3.36,4.10) - - Ventricularexpansionrate,mL/y 0-12mo 1.29(1.05,1.53) 1.41(1.20,1.62) 2.44(1.98,2.91) 2.83(2.55,3.11) 4.31(3.55,5.08) 4.48(3.85,5.11) 12-24mo 1.72(1.38,2.05) 1.53(1.36,1.71) 2.78(2.33,3.23) 3.10(2.84,3.36) 5.48(4.67,6.28) 5.36(4.69,6.03) 24-36mo 1.49(1.09,1.90) 1.66(1.43,1.89) 3.43(2.91,3.95) 3.37(3.05,3.70) - - Abbreviations:AD5Alzheimerdisease;CI5confidenceinterval;MCI5mildcognitiveimpairment. aThemean(and95%CI)atrophyrateswerecalculatedusingdataonlyfromsubjectswithavailablescanpairsformonths0-12,12-24,and24-36, whereasthemodelestimateswerecalculatedusingallthedata. toaclinicaldiagnosisofADwithin3years)andMCI-S 0.25], p 5 0.91) (see table 5), and an interaction test (MCI subjects that remained in MCI within 3 years). formally comparing these showed evidence that they Table1showsthedemographicsofthesubjectsaccord- differed(p5 0.038).Althoughnotstatisticallysignifi- ing to the clinical progression of the disease, MMSE cantlydifferent(p50.38),theestimatedaccelerationin scoreatbaseline,andthenumberofscanpairsavailable. ventricular expansion was also greater in the MCI-P The mean atrophy rates of the MCI-S subjects were subjects (0.37 mL/year2 [95% CI 0.10, 0.65], p 5 moresimilartocontrols,whereasthemeanatrophyrates 0.007) than in the MCI-S subjects (0.22 mL/year2 of MCI-P subjects were more similar to AD subjects [95%CI0.05,0.40],p50.011). (seetable4).Therewasstatisticallysignificantevidence ofaccelerationforhippocampallossinMCI-Psubjects DISCUSSION Using data from the ADNI, we have (0.50%/year2[95%CI0.17,0.83],p50.003),butnot investigatedaccelerationinratesofwhole-brainandhip- in MCI-S subjects (20.02%/year2 [95% CI 20.28, pocampal atrophy and ventricular enlargement, using Table3 Model-estimatedatrophyrateatbaselineandaccelerationratebasedonlinearmixedmodelsa Control,n5205 MCI,n5352 AD,n5156 Brain Atrophyrate,baseline,%/y 0.63(0.53,0.72) 1.01(0.92,1.10) 1.41(1.23,1.59) Accelerationinrate,%/y2 20.01(20.07,0.05) 0.01(20.04,0.06) 0.09(20.07,0.25) pValueforacceleration 0.68 0.72 0.26 Hippocampus Atrophyrate,baseline,%/y 1.22(0.90,1.55) 3.20(2.82,3.57) 5.19(4.44,5.94) Accelerationinrate,%/y2 0.06(20.13,0.26) 0.22(0.01,0.42) 0.49(20.20,1.17) pValueforacceleration 0.53 0.037 0.16 Ventricles Expansionrate,baseline,mL/y 1.34(1.09,1.60) 2.69(2.38,3.01) 4.04(3.34,4.75) Accelerationrate,mL/y2 0.13(20.004,0.26) 0.27(0.12,0.43) 0.88(0.47,1.29) pValueforacceleration 0.06 0.001 ,0.001 Abbreviations:AD=Alzheimerdisease;MCI=mildcognitiveimpairment. aDataaremean(95%confidenceinterval). Neurology80 February12,2013 651 (cid:170)(cid:1)(cid:19)(cid:17)(cid:18)(cid:20)(cid:1)(cid:34)(cid:78)(cid:70)(cid:83)(cid:74)(cid:68)(cid:66)(cid:79)(cid:1)(cid:34)(cid:68)(cid:66)(cid:69)(cid:70)(cid:78)(cid:90)(cid:1)(cid:80)(cid:71)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90)(cid:15)(cid:1)(cid:54)(cid:79)(cid:66)(cid:86)(cid:85)(cid:73)(cid:80)(cid:83)(cid:74)(cid:91)(cid:70)(cid:69)(cid:1)(cid:83)(cid:70)(cid:81)(cid:83)(cid:80)(cid:69)(cid:86)(cid:68)(cid:85)(cid:74)(cid:80)(cid:79)(cid:1)(cid:80)(cid:71)(cid:1)(cid:85)(cid:73)(cid:74)(cid:84)(cid:1)(cid:66)(cid:83)(cid:85)(cid:74)(cid:68)(cid:77)(cid:70)(cid:1)(cid:74)(cid:84)(cid:1)(cid:81)(cid:83)(cid:80)(cid:73)(cid:74)(cid:67)(cid:74)(cid:85)(cid:70)(cid:69)(cid:15) Table4 AnnualizedatrophyrateforsubjectswithMCI,accordingtotheclinicalprogressionofthediseasea MCI-S MCI-P Mean(95%CI), Modelestimate Mean(95%CI), Modelestimate n546 (95%CI),n5185 n551 (95%CI),n5147 Brainatrophyrate,%/y 0-12mo 0.59(0.42,0.76) 0.82(0.74,0.91) 1.17(0.98,1.37) 1.25(1.13,1.38) 12-24mo 0.86(0.66,1.07) 0.83(0.76,0.90) 1.20(0.96,1.44) 1.28(1.18,1.38) 24-36mo 0.82(0.59,1.05) 0.83(0.72,0.94) 1.37(1.13,1.62) 1.30(1.16,1.45) Hippocampalatrophyrate,%/y 0-12mo 2.70(1.94,3.46) 2.58(2.22,2.95) 4.51(3.77,5.26) 4.26(3.79,4.73) 12-24mo 2.63(1.67,3.59) 2.57(2.24,2.90) 4.88(3.95,5.80) 4.73(4.33,5.14) 24-36mo 2.66(1.80,3.51) 2.55(2.09,3.01) 5.11(4.40,5.82) 5.21(4.65,5.76) Ventricularexpansionrate,mL/y 0-12mo 1.64(1.16,2.13) 2.27(1.93,2.60) 3.29(2.53,4.06) 3.57(3.12,4.02) 12-24mo 2.39(1.89,2.89) 2.49(2.17,2.81) 3.39(2.64,4.15) 3.94(3.54,4.35) 24-36mo 2.16(1.75,2.56) 2.71(2.32,3.10) 3.75(3.10,4.39) 4.32(3.80,4.84) Abbreviations:CI5confidenceinterval;MCI5mildcognitiveimpairment;MCI-P5MCIsubjectsobservedtoprogresstoa clinicaldiagnosisofAlzheimerdiseasewithin3years;MCI-S5MCIsubjectsobservedtoremaininMCIwithin3years. aThemean(and95%CI)atrophyrateswerecalculatedusingdataonlyfromsubjectswithavailablescanpairsformonths 0-12,12-24and24-36,whereasthemodelestimates(95%CI)werecalculatedusingallthedata. 3-year follow-up data on controls and subjects with AD subjects were estimated to accelerate at 0.27 and MCI and 2-year follow-up data for subjects with AD. 0.88mL/year2,respectively. We have assessed acceleration using all available data Previousstudiesinvestigatingthetimecourseofhip- by using linear mixed models. The clinically defined pocampalvolumelossasafunctionoftimefrombaseline groups of subjects-controls, MCI, and AD-showed havereportedconflictingresults.9,10,26Using0-,6-,and theexpectedgroupdifferencesinmeanratesofatrophy 12-month magnetic resonance scans from the ADNI, atbaseline:brainatrophyrateswere;2.4timesgreater hippocampal atrophy rates were estimated to accelerate in the AD subjects than in the controls, ventricular by26.5mm3/year2(or1.6%)insubjectswithADand enlargement was ;3 times greater, and hippocampal 12.1 mm3/year2 (or 0.6%) in subjects with MCI, but atrophy was ;4.3 times greater (table 3). The MCI remained constant in controls.9 Another study found group rates fell almost exactly halfway between the thathippocampalatrophyrateincontrols(aged49-85 ADandcontrolmeansforeachofthemeasures. years)acceleratedfrom30mm3/yearto124mm3/yearin HippocampalatrophyinsubjectswithMCIwasesti- approximately 15 months,10 although the annual per- mated to accelerate by 0.22%/year2 (p 5 0.037) on centage change from the first to second follow-up was average. Furthermore, in the subjects with MCI who approximately4%,whichwassimilartotheratesinAD subsequentlyweregivenadiagnosisofAD,theacceler- subjectsreportedbyanADNIstudy.9Suchacceleration ationwastwicethisat0.50%/year2(p50.003)andwas maybedrivenbytheoldercontrolsubjects.Inaddition, verysimilartothatseenintheADgroup(0.49%/year2, acceleratinghippocampalatrophywasfoundinthecon- p50.16).Thissuggeststhattheobservedaccelerationof trol,MCI,andADsubjectswithAD-likeCSFmolecular hippocampal loss in MCI subjects is mainly driven by profilesusing0-,6-,and12-monthmagneticresonance theMCIsubjectsthatwereobservedtoprogresstoclin- scans from ADNI.11 However, using 0-, 6-, and 12- ical ADwithin3years.Althoughthe estimatedhippo- monthmagneticresonancescansfromthecontrolsand campalaccelerationinADsubjectswasmoderatelylarge, MCI subjectsinADNI, the intercept oftheregression therewasnostatisticallysignificantevidencethatitdif- lineassumingnoaccelerationfittedtothevolumelossof fered from zero. However, this may be because of thehippocampusat6and12monthswasclosetozero.26 reduced power due to the shorter period of follow-up ThisimpliesthattheatrophyratesincontrolsandMCI (only2yearsasopposedto3fortheMCIgroup)and/or subjectsstaynearlythesameover1year.Differencesin greaterheterogeneityintheADgroup,e.g.,aproportion results between studies regarding acceleration may be ofADsubjectsmaynolongerbeacceleratinginhippo- attributable to differences in the number of subjects, campal atrophy as suggested in the sigmoid model.5 the number of time points, and the hippocampal As for ventricular expansion, the rates in MCI and segmentation protocol used. To address the latter, the 652 Neurology80 February12,2013 (cid:170)(cid:1)(cid:19)(cid:17)(cid:18)(cid:20)(cid:1)(cid:34)(cid:78)(cid:70)(cid:83)(cid:74)(cid:68)(cid:66)(cid:79)(cid:1)(cid:34)(cid:68)(cid:66)(cid:69)(cid:70)(cid:78)(cid:90)(cid:1)(cid:80)(cid:71)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90)(cid:15)(cid:1)(cid:54)(cid:79)(cid:66)(cid:86)(cid:85)(cid:73)(cid:80)(cid:83)(cid:74)(cid:91)(cid:70)(cid:69)(cid:1)(cid:83)(cid:70)(cid:81)(cid:83)(cid:80)(cid:69)(cid:86)(cid:68)(cid:85)(cid:74)(cid:80)(cid:79)(cid:1)(cid:80)(cid:71)(cid:1)(cid:85)(cid:73)(cid:74)(cid:84)(cid:1)(cid:66)(cid:83)(cid:85)(cid:74)(cid:68)(cid:77)(cid:70)(cid:1)(cid:74)(cid:84)(cid:1)(cid:81)(cid:83)(cid:80)(cid:73)(cid:74)(cid:67)(cid:74)(cid:85)(cid:70)(cid:69)(cid:15) allowedforatrophyratestovarybetweensubjects,but Table5 Model-estimatedatrophyrateatbaselineandaccelerationratebased assumedthatanyaccelerationwasthesameforallsub- onlinearmixedmodelsinsubjectswithMCI,accordingtotheclinical progressionofthediseasea jects.Furtheranalysiswithlongerfollow-upwillpermit modelstobefittedthatallowacceleration(ordecelera- MCI-S,n5185 MCI-P,n5147 tion)inratestovarybothwithinandbetweensubjects, Brain which may provide evidence regarding the validity of Atrophyrate,baseline,%/y 0.82(0.71,0.93) 1.24(1.09,1.39) differentmodelsofprogression. Accelerationrate,%/y2 0.005(20.07,0.08) 0.03(20.06,0.11) Ouranalysishasanumberofstrengthsandlimita- tions.Statisticalpowertodetectaccelerationinatrophy pValueforacceleration 0.88 0.57 ratesisstronglyaffectedbythelengthoftimeoverwhich Hippocampus subjectsarefollowed,whichwasrelativelyshort,partic- Atrophyrate,baseline,%/y 2.59(2.15,3.04) 4.02(3.45,4.60) ularlyfortheADsubjects.Despitethis,ourestimatesof Accelerationrate,%/y2 20.02(20.28,0.25) 0.50(0.17,0.83) accelerationhaverelativelynarrowCIs.Aproportionof pValueforacceleration 0.91 0.003 subjectsineachgrouphadmissingscansatoneormore Ventricles follow-uptimepoints,causingalossofinformationand potentiallybiasingourresults.However,wehaveuseda Expansionrate,baseline,mL/y 2.15(1.78,2.52) 3.38(2.85,3.91) statisticalmodelingtechniquethataccommodatessuch Accelerationrate,mL/y2 0.22(0.05,0.40) 0.37(0.10,0.65) missingness under the missing at random assumption. pValueforacceleration 0.011 0.007 Wehaveusedaconsistentatrophymeasurementtech- Abbreviations:MCI5mildcognitiveimpairment;MCI-P5MCIsubjectsobservedtopro- niquethattreatseachtimepointequally,whichavoids gresstoaclinicaldiagnosisofAlzheimerdiseasewithin3years;MCI-S5MCIsubjects bias toward any particular time point. Our analysis observedtoremaininMCIwithin3years. hasuseddatafromalargenumberofsubjectswithstan- aDataaremean(95%confidenceinterval). dardizedandconsistentprotocolsusedforimagingand “harmonization of hippocampal segmentation” project diagnosis. was recently set up to develop a harmonized protocol Overall, we have found evidence of acceleration in thataimstoreducethepresentheterogeneityinhippo- hippocampal atrophy rates in subjects with MCI in campalsegmentationprotocols.27 theADNI.Thisaccelerationseemstobedrivenbythose Many studies have investigated the time course subjectswithMCIwhosubsequentlyreceivedaclinical of brain tissue loss as a function of age or other diagnosis of AD dementia within 3 years. The rate of characteristics.3,4,6-8,28,29 Using data from young acceleration of hippocampal atrophy is relatively slow adult familial AD patients, hippocampal atrophy was compared with the difference in atrophy rates in con- estimatedtoaccelerateby0.40%/year2(95%CI0.17, trols and clinical AD. This suggests a long period of 0.63),whichissimilartoourestimateof0.49%/year2.4 transition to the pathologic losses seen in clinical AD, In the same study, the authors found evidence that providedaccelerationinratesisconstant.Ratesofven- whole-brain atrophy rates accelerated by 0.26%/year2 tricularenlargementwerefoundtoincreaseovertimein (95%CI0.16,0.37),anestimatethatfallsjustoutside bothMCIandADsubjects.Ourfindingsgivefurther the 95%CI weobtainedinthisstudy.Thismightbe motivation for future longitudinal studies that will attributable to a more aggressive onset to the familial enable investigation of how atrophy rates evolve disease-perhapsconsistentwithanageatonsetthatis throughoutthecourseofAD. some30or40yearsearlierthantheageatonsetinlate- onset sporadic AD in ADNI-or to the fact that the AUTHORCONTRIBUTIONS clinically defined AD (dementia thought to be due to Dr.Leungperformedtheimageanalysisandwrotethemanuscript.Dr.Bar- tlettperformedthestatisticalanalysis,gaveadvice,andeditedthemanuscript. AD)groupinADNIinevitablycontainsaproportionof Dr.Barnes,Ms.Manning,andDr.Ourselingaveadviceandeditedtheman- subjectswhodonothaveADpathologically. uscript.Dr.Foxconceivedthestudy,gaveadvice,andeditedthemanuscript. Recently it was hypothesized that the dynamics of cerebraltissuelosswithinindividualsfollowsanonlinear ACKNOWLEDGMENT DatacollectionandsharingforthisprojectwasfundedbytheAlzheimer’sDis- andsigmoidaltrajectory.5Severalstudieshaveattempted easeNeuroimagingInitiative(ADNI)(NIHgrantU01AG024904).ADNIis to fit sigmoidal models for the trajectory of cerebral fundedbytheNationalInstituteonAging,theNationalInstituteofBiomedical tissue loss (e.g., hippocampus and cortical thickness) ImagingandBioengineering,andthroughgenerouscontributionsfromthefol- using cross-sectional data from ADNI.11,30,31 The sig- lowing:Abbott;Alzheimer’sAssociation;Alzheimer’sDrugDiscoveryFounda- tion;AmorfixLifeSciencesLtd.;AstraZeneca;BayerHealthCare;BioClinica, moidalmodelimpliesthatatrophyrateswithinasubject Inc.;BiogenIdecInc.;Bristol-MyersSquibbCompany;EisaiInc.;ElanPhar- initiallyincreasefromzero,remainconstantforaperiod, maceuticalsInc.;EliLillyandCompany;F.Hoffmann-LaRocheLtdandits and then eventually decrease to zero. In the current affiliatedcompanyGenentech,Inc.;GEHealthcare;Innogenetics,N.V.;IXICO study,we modeledthetrajectoryofcerebraltissueloss Ltd.;JanssenAlzheimerImmunotherapyResearch&Development,LLC;John- son&JohnsonPharmaceuticalResearch&DevelopmentLLC;Medpace,Inc.; ineachdiseasegroupusinglongitudinaldatafromAD- Merck&Co.,Inc.;MesoScaleDiagnostics,LLC;NovartisPharmaceuticals NIovera2-or3-yearperiod.Ourlinearmixedmodel Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Neurology80 February12,2013 653 (cid:170)(cid:1)(cid:19)(cid:17)(cid:18)(cid:20)(cid:1)(cid:34)(cid:78)(cid:70)(cid:83)(cid:74)(cid:68)(cid:66)(cid:79)(cid:1)(cid:34)(cid:68)(cid:66)(cid:69)(cid:70)(cid:78)(cid:90)(cid:1)(cid:80)(cid:71)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90)(cid:15)(cid:1)(cid:54)(cid:79)(cid:66)(cid:86)(cid:85)(cid:73)(cid:80)(cid:83)(cid:74)(cid:91)(cid:70)(cid:69)(cid:1)(cid:83)(cid:70)(cid:81)(cid:83)(cid:80)(cid:69)(cid:86)(cid:68)(cid:85)(cid:74)(cid:80)(cid:79)(cid:1)(cid:80)(cid:71)(cid:1)(cid:85)(cid:73)(cid:74)(cid:84)(cid:1)(cid:66)(cid:83)(cid:85)(cid:74)(cid:68)(cid:77)(cid:70)(cid:1)(cid:74)(cid:84)(cid:1)(cid:81)(cid:83)(cid:80)(cid:73)(cid:74)(cid:67)(cid:74)(cid:85)(cid:70)(cid:69)(cid:15) Company.TheCanadianInstitutesofHealthResearchisprovidingfundsto 13. JovicichJ,CzannerS,GreveD,etal.Reliabilityinmulti- supportADNIclinicalsitesinCanada.Privatesectorcontributionsarefacilitated sitestructuralMRIstudies:effectsofgradientnon-linear- bytheFoundationfortheNIH(www.fnih.org).Thegranteeorganizationisthe itycorrectiononphantomandhumandata.Neuroimage NorthernCaliforniaInstituteforResearchandEducation,andthestudyis 2006;30:436-443. coordinatedbytheAlzheimer’sDiseaseCooperativeStudyattheUniversityof 14. Narayana PA, Brey WW, Kulkarni MV, Sievenpiper CL. California,SanDiego.ADNIdataaredisseminatedbytheLaboratoryforNeuro Compensationforsurfacecoilsensitivityvariationinmagnetic ImagingattheUniversityofCalifornia,LosAngeles.Thisresearchwasalso resonanceimaging.MagnResonImaging1988;6:271-274. supportedbyNIHgrantsP30AG010129andK01AG030514.Theresearch 15. SledJG,ZijdenbosAP,EvansAC.Anonparametricmethod was supported by the National Institute for Health Research Biomedical ResearchUnitinDementiabasedatUCLH/UCL,theMedicalResearchCoun- forautomaticcorrectionofintensitynonuniformityinMRI cil,Alzheimer’sResearchUK,andADNI.TheDementiaResearchCentreisan data.IEEETransMedImaging1998;17:87-97. Alzheimer’sResearchUKCo-ordinatingCentreandhasalsoreceivedequipment 16. GunterJL,BernsteinMA,BorowskiBJ,etal.Validation fundedbytheAlzheimer’sResearchUK.Theauthorsthanktheimageanalysts testing of the MRI calibration phantom for the Alz- andtheresearchassociatesintheDementiaResearchCentrefortheirhelpinthe heimer’sDiseaseNeuroimagingInitiativeStudy.ISMRM study,andtheADNIstudysubjectsandinvestigatorsfortheirparticipation. 14thScientificMeetingandExhibition;2006. 17. FreeboroughPA,FoxNC.Theboundaryshiftintegral:an accurateandrobustmeasureofcerebralvolumechangesfrom STUDYFUNDING registeredrepeatMRI.IEEETransMedImaging1997;16: Notargetedfundingreported. 623-629. 18. LeungKK,ClarksonMJ,BartlettJW,etal.Robustatro- DISCLOSURE phyratemeasurementinAlzheimer’sdiseaseusingmulti- K.Leung,J.Bartlett,J.Barnes,E.Manning,andS.Ourselinreportnodis- siteserialMRI:tissue-specificintensitynormalizationand closure.N.Foxreportsthathisresearchhasreceivedpaymentforconsul- parameterselection.Neuroimage2010;50:516-523. tancyorforimageanalysisservicesfromAvid/Lilly,BMS,Elan/Janssen, 19. Leung KK, Barnes J, Modat M, et al. Brain MAPS: an GE,Lundbeck,andPfizer/Wyeth.GotoNeurology.orgforfulldisclosures. automated,accurateandrobustbrainextractiontechnique usingatemplatelibrary.Neuroimage2011;55:1091-1108. ReceivedJuly24,2012.AcceptedinfinalformOctober10,2012. 20. LeungKK,BarnesJ,RidgwayGR,etal.Automatedcross- sectionalandlongitudinalhippocampalvolumemeasurement REFERENCES inmildcognitiveimpairmentandAlzheimer’sdisease.Neuro- 1. Fox NC, Schott JM. Imaging cerebral atrophy: normal image2010;51:1345-1359. ageingtoAlzheimer’sdisease.Lancet2004;363:392-394. 21. Freeborough PA, Fox NC, Kitney RI. Interactive algo- 2. JackCRJr,ShiungMM,GunterJL,etal.Comparisonof rithms for the segmentation and quantitation of 3-D differentMRIbrainatrophyratemeasureswithclinicaldisease MRI brain scans. Comput Methods Programs Biomed progressioninAD.Neurology2004;62:591-600. 1997;53:15-25. 3. JackCRJr,WeigandSD,ShiungMM,etal.Atrophyrates 22. LeungKK,RidgwayGR,OurselinS,FoxNC.Consistent accelerateinamnesticmildcognitiveimpairment.Neurology multi-time-point brain atrophy estimation from the 2008;70(19pt2):1740-1752. boundaryshiftintegral.Neuroimage2012;59:3995-4005. 4. Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy 23. Lewis EB, Fox NC. Correction of differential intensity progressioninfamilialAlzheimer’sdisease:aserialMRIstudy. inhomogeneity in longitudinal MR images. Neuroimage LancetNeurol2006;5:828-834. 2004;23:75-83. 5. JackCRJr,KnopmanDS,JagustWJ,etal.Hypothetical 24. FrostC,KenwardMG,FoxNC.Theanalysisofrepeated model of dynamic biomarkers of the Alzheimer’s patho- ‘direct’measuresofchangeillustratedwithanapplication logicalcascade.LancetNeurol2010;9:119-128. inlongitudinalimaging.StatMed2004;23:3275-3286. 6. DriscollI,DavatzikosC,AnY,etal.Longitudinalpattern 25. Verbeke G, Molenberghs G. Linear Mixed Models for of regional brain volume change differentiates normal LongitudinalData.NewYork:Springer;2000. agingfromMCI.Neurology2009;72:1906-1913. 26. YushkevichPA,AvantsBB,DasSR,PlutaJ,AltinayM, 7. McDonald CR, McEvoy LK, Gharapetian L, et al. CraigeC.Biasinestimationofhippocampalatrophyusing Regional rates of neocortical atrophy from normal aging deformation-based morphometry arises from asymmetric toearlyAlzheimerdisease.Neurology2009;73:457-465. global normalization: an illustration in ADNI 3 T MRI 8. CarlsonNE,MooreMM,DameA,etal.Trajectoriesof data.Neuroimage2010;50:434-445. brain loss in aging and the development of cognitive 27. FrisoniGB,JackCR.Harmonizationofmagneticresonance- impairment.Neurology2008;70:828-833. basedmanualhippocampalsegmentation:amandatorystep 9. SchuffN,WoernerN,BoretaL,etal.MRIofhippocampal forwideclinicaluse.AlzheimersDement2011;7:171-174. volumelossinearlyAlzheimer’sdiseaseinrelationtoApoE 28. ChanD,JanssenJC,WhitwellJL,etal.Changeinratesof genotypeandbiomarkers.Brain2009;132(pt4):1067-1077. cerebralatrophyovertimeinearly-onsetAlzheimer’sdisease: 10. Raz N, Ghisletta P, Rodrigue KM, Kennedy KM, longitudinalMRIstudy.Lancet2003;362:1121-1122. LindenbergerU.Trajectoriesofbrainaging inmiddle-aged 29. MoriE,LeeK,YasudaM,etal.Acceleratedhippocampal andolderadults:regionalandindividualdifferences.Neuro- atrophyinAlzheimer’sdiseasewithapolipoproteinEepsi- image2010;51:501-511. lon4allele.AnnNeurol2002;51:209-214. 11. SabuncuMR,DesikanRS,SepulcreJ,etal.Thedynamicsof 30. SchuffN,TosunD,InselPS,etal.Nonlineartimecourse corticalandhippocampalatrophyinAlzheimerdisease.Arch ofbrainvolume lossincognitivelynormaland impaired Neurol2011;68:1040-1048. elders.NeurobiolAging2010;33:845-855. 12. JackCRJr,BernsteinMA,FoxNC,etal.TheAlzheimer’s 31. CaroliA,FrisoniGB.ThedynamicsofAlzheimer’sdisease DiseaseNeuroimagingInitiative(ADNI):MRImethods. biomarkersintheAlzheimer’sDiseaseNeuroimagingIni- JMagnResonImaging2008;27:685-691. tiativecohort.NeurobiolAging2010;31:1263-1274. 654 Neurology80 February12,2013 (cid:170)(cid:1)(cid:19)(cid:17)(cid:18)(cid:20)(cid:1)(cid:34)(cid:78)(cid:70)(cid:83)(cid:74)(cid:68)(cid:66)(cid:79)(cid:1)(cid:34)(cid:68)(cid:66)(cid:69)(cid:70)(cid:78)(cid:90)(cid:1)(cid:80)(cid:71)(cid:1)(cid:47)(cid:70)(cid:86)(cid:83)(cid:80)(cid:77)(cid:80)(cid:72)(cid:90)(cid:15)(cid:1)(cid:54)(cid:79)(cid:66)(cid:86)(cid:85)(cid:73)(cid:80)(cid:83)(cid:74)(cid:91)(cid:70)(cid:69)(cid:1)(cid:83)(cid:70)(cid:81)(cid:83)(cid:80)(cid:69)(cid:86)(cid:68)(cid:85)(cid:74)(cid:80)(cid:79)(cid:1)(cid:80)(cid:71)(cid:1)(cid:85)(cid:73)(cid:74)(cid:84)(cid:1)(cid:66)(cid:83)(cid:85)(cid:74)(cid:68)(cid:77)(cid:70)(cid:1)(cid:74)(cid:84)(cid:1)(cid:81)(cid:83)(cid:80)(cid:73)(cid:74)(cid:67)(cid:74)(cid:85)(cid:70)(cid:69)(cid:15)
